Physician profile
Wesley Hard
NPI 1689630329
$2,307.67
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $613 · 2021: $787 · 2022: $310.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $727.64 | 2019-2022 | |
| Novo Nordisk INC | $241.53 | 2019-2022 | |
| Abbvie INC. | $192.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $117.98 | 2019-2022 | |
| Lilly USA, LLC | $113.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.38 | 2019-2022 | |
| Abbott Laboratories | $100.58 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $95.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.42 | 2019-2021 | |
| Amgen INC. | $72.32 | 2019-2022 | |
| Circassia INC. | $64.30 | 2019-2020 | |
| Allergan, INC. | $52.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.02 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $41.45 | 2019 | |
| Mylan Specialty L.P. | $35.77 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $34.57 | 2022 | |
| Amarin Pharma, INC. | $33.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.43 | 2020 | |
| Eisai INC. | $24.25 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $21.46 | 2021 | |
| Boston Scientific Corporation | $15.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.79 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.35 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.33 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Hard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.